Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib plus osimertinib versus placebo plus osimertinib as first-line treatment for EGFR-mutant, MET-positive advanced or metastatic non-small cell lung cancer
CTR20211427Phase 3Active
- Sponsor
- HUTCHMED
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by HUTCHMED. Started Sep 2021; status: active.
02
Drugs
savolitinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211427.